Cargando…

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer

INTRODUCTION: Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic mann...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Karen J, Sims, Andrew H, Liang, Liang, Faratian, Dana, Muir, Morwenna, Walker, Graeme, Kuske, Barbara, Dixon, J Michael, Cameron, David A, Harrison, David J, Langdon, Simon P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917034/ https://www.ncbi.nlm.nih.gov/pubmed/20569502 http://dx.doi.org/10.1186/bcr2593

Ejemplares similares

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation
por: Meyer, Colette, et al.
Publicado: (2013)

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis
por: Verleyen, Wim, et al.
Publicado: (2015)

Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer
por: Huang, Rui, et al.
Publicado: (2014)

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy
por: Faratian, Dana, et al.
Publicado: (2011)

Diversity of Matriptase Expression Level and Function in Breast Cancer
por: Welman, Arkadiusz, et al.
Publicado: (2012)

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines
por: Morgan, Kevin, et al.
Publicado: (2011)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers
por: Briffa, Romina, et al.
Publicado: (2015)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
por: Lebedeva, Galina, et al.
Publicado: (2012)

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen
por: Lebedeva, Galina, et al.
Publicado: (2012)

Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
por: Langdon, Simon P., et al.
Publicado: (2019)

Systems pathology
por: Faratian, Dana
Publicado: (2010)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
por: Faratian, Dana, et al.
Publicado: (2011)

C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target
por: Katz, E, et al.
Publicado: (2008)

Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
por: Gallo, Ciro, et al.
Publicado: (2006)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

Unveiling the Impact of Morphine on Tamoxifen Metabolism in Mice in vivo
por: Gabel, Florian, et al.
Publicado: (2020)

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
por: Langdon, S. P., et al.
Publicado: (1990)

In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control
por: Felker, Anastasia, et al.
Publicado: (2016)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Experiences of living with postural tachycardia syndrome
por: Waterman, Samantha, et al.
Publicado: (2021)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Tamoxifen to treat male pubertal gynaecomastia
por: Zehetner, Anthony
Publicado: (2015)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

The Use of Automated Quantitative Analysis to Evaluate Epithelial-to-Mesenchymal Transition Associated Proteins in Clear Cell Renal Cell Carcinoma
por: O'Mahony, Fiach C., et al.
Publicado: (2012)

Preventing the co-prescription of tamoxifen and fluoxetine in General Practice
por: Stonier, Thomas, et al.
Publicado: (2013)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients
por: Mullooly, Maeve, et al.
Publicado: (2019)

Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer
por: Koussounadis, A, et al.
Publicado: (2014)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

IARC on tamoxifen.
Publicado: (1996)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo
por: Nilsson Åberg, Ulrika W., et al.
Publicado: (2011)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ib57r59p2l97srk8st31mfiq0v